Inibitori delle JAK (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inibitori delle JAK" in Italian language version.

refsWebsite

Global rank Italian rank

21nih.gov

4^th place

9^th place

19doi.org

2^nd place

7^th place

12oadoi.org

799^th place

22^nd place

8clinicaltrials.gov

5,225^th place

5,296^th place

3web.archive.org

1^st place

2pfizer.com

low place

1medpagetoday.com

9,274^th place

low place

1jakafi.com

low place

1zoetisus.com

low place

1lilly.com

low place

1fda.gov

447^th place

644^th place

1abbvie.com

low place

1medchemexpress.com

low place

1aacrjournals.org

8,869^th place

7,853^rd place

1yale.edu

565^th place

723^rd place

1harvard.edu

18^th place

104^th place

aacrjournals.org

cancerres.aacrjournals.org

Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM, Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice, in Cancer Research, vol. 63, n. 6, marzo 2003, pp. 1270-9, PMID 12649187.

abbvie.com

news.abbvie.com

(EN) AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis | AbbVie News Center, su news.abbvie.com. URL consultato il 16 agosto 2019.

clinicaltrials.gov

Clinical Trials with PF04965842, su clinicaltrials.gov. URL consultato il 21 maggio 2017.
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1), su clinicaltrials.gov. URL consultato il 21 novembre 2019.
Clinical Trials with GLPG0634, su clinicaltrials.gov. URL consultato il 16 luglio 2016.
Clinical trials with LY2784544 (Gandotinib), su clinicaltrials.gov. URL consultato il 16 luglio 2016.
Momelotinib in Transfusion-Dependent Adults with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF), su clinicaltrials.gov. URL consultato il 16 luglio 2016.
Momelotinib Combined with Capecitabine and Oxaliplatin in Adults with Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma, su clinicaltrials.gov. URL consultato il 16 luglio 2016.
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis with Thrombocytopenia, su clinicaltrials.gov. URL consultato il 16 luglio 2016.
Pacritinib in Combination with Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS), su clinicaltrials.gov. URL consultato il 16 luglio 2016.

doi.org

dx.doi.org

Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ, Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease, in Current Opinion in Pharmacology, vol. 12, n. 4, agosto 2012, pp. 464-70, DOI:10.1016/j.coph.2012.06.008, PMC 3419278, PMID 22819198.
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ, Therapeutic targeting of Janus kinases, in Immunological Reviews, vol. 223, giugno 2008, pp. 132-42, DOI:10.1111/j.1600-065X.2008.00644.x, PMC 2634846, PMID 18613833.
Norman P, Selective JAK inhibitors in development for rheumatoid arthritis, in Expert Opinion on Investigational Drugs, vol. 23, n. 8, agosto 2014, pp. 1067-77, DOI:10.1517/13543784.2014.918604, PMID 24818516.
Forster M, Gehringer M, Laufer SA, Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting, in Bioorganic & Medicinal Chemistry Letters, vol. 27, n. 18, settembre 2017, pp. 4229-4237, DOI:10.1016/j.bmcl.2017.07.079, PMID 28844493.
Vaddi K, Sarlis NJ, Gupta V, Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis, in Expert Opinion on Pharmacotherapy, vol. 13, n. 16, novembre 2012, pp. 2397-407, DOI:10.1517/14656566.2012.732998, PMID 23051187.
Ostojic A, Vrhovac R, Verstovsek S, Ruxolitinib for the treatment of myelofibrosis, in Drugs of Today, vol. 47, n. 11, novembre 2011, pp. 817-27, DOI:10.1358/dot.2011.47.11.1708829, PMID 22146225.
Mesa RA, Yasothan U, Kirkpatrick P, Ruxolitinib, in Nature Reviews. Drug Discovery, vol. 11, n. 2, febbraio 2012, pp. 103-4, DOI:10.1038/nrd3652, PMID 22293561.
Zerbini CA, Lomonte AB, Tofacitinib for the treatment of rheumatoid arthritis, in Expert Review of Clinical Immunology, vol. 8, n. 4, maggio 2012, pp. 319-31, DOI:10.1586/eci.12.19, PMID 22607178.
Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M, Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, in Journal of Veterinary Pharmacology and Therapeutics, vol. 37, n. 4, agosto 2014, pp. 317-24, DOI:10.1111/jvp.12101, PMC 4265276, PMID 24495176.
Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A, Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate, in Arthritis & Rheumatology, vol. 69, n. 4, aprile 2017, pp. 709-719, DOI:10.1002/art.39955, PMID 27748083.
Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH, Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis, in Arthritis & Rheumatology, vol. 69, n. 5, maggio 2017, pp. 932-942, DOI:10.1002/art.40054, PMID 28118538.
Markham A, Keam SJ, Peficitinib: First Global Approval, in Drugs, vol. 79, n. 8, giugno 2019, pp. 887-891, DOI:10.1007/s40265-019-01131-y, PMID 31093950.
Liu D, Mamorska-Dyga A, Syk inhibitors in clinical development for hematological malignancies, in Journal of Hematology & Oncology, vol. 10, n. 1, luglio 2017, p. 145, DOI:10.1186/s13045-017-0512-1, PMC 5534090, PMID 28754125.
Shabbir M, Stuart R, Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside, in Expert Opinion on Investigational Drugs, vol. 19, n. 3, marzo 2010, pp. 427-36, DOI:10.1517/13543781003598862, PMID 20141349.
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW, SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies, in Leukemia, vol. 25, n. 11, novembre 2011, pp. 1751-9, DOI:10.1038/leu.2011.148, PMID 21691275.
Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL, CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms, in Cancer Cell, vol. 28, n. 1, luglio 2015, pp. 15-28, DOI:10.1016/j.ccell.2015.06.006, PMC 4503933, PMID 26175413.
Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM, Pharmacologic inhibition of JAK-STAT signaling promotes hair growth, in Science Advances, vol. 1, n. 9, ottobre 2015, pp. e1500973, Bibcode:2015SciA....1E0973H, DOI:10.1126/sciadv.1500973, PMC 4646834, PMID 26601320.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A, Janus kinase inhibitors in dermatology: A systematic review, in Journal of the American Academy of Dermatology, vol. 76, n. 4, aprile 2017, pp. 745–753.e19, DOI:10.1016/j.jaad.2016.12.004, PMID 28169015.
Furumoto Y, Gadina M, The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders, in BioDrugs, vol. 27, n. 5, ottobre 2013, pp. 431-8, DOI:10.1007/s40259-013-0040-7, PMC 3778139, PMID 23743669.

fda.gov

(EN) FDA approves treatment for patients with rare bone marrow disorder, su FDA, 16 agosto 2019. URL consultato il 16 agosto 2019.

harvard.edu

adsabs.harvard.edu

Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM, Pharmacologic inhibition of JAK-STAT signaling promotes hair growth, in Science Advances, vol. 1, n. 9, ottobre 2015, pp. e1500973, Bibcode:2015SciA....1E0973H, DOI:10.1126/sciadv.1500973, PMC 4646834, PMID 26601320.

jakafi.com

Jakafi (ruxolitinib) Tablets, for Oral Use. Full Prescribing Information (PDF), su jakafi.com, Incyte Corporation. Wilmington, DE 19803. URL consultato il 16 luglio 2016.

lilly.com

investor.lilly.com

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis, su Eli Lilly and Company, 1º giugno 2018. URL consultato il 21 agosto 2018.

medchemexpress.com

Abrocitinib (PF-04965842), su medchemexpress.com, MedChemExpress. URL consultato il 21 novembre 2019.

medpagetoday.com

JAK Inhibitors Showing Promise for Many Skin Problems - Conditions ranging from alopecia to vitiligo, su medpagetoday.com, 6 luglio 2017.

nih.gov

ncbi.nlm.nih.gov

Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ, Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease, in Current Opinion in Pharmacology, vol. 12, n. 4, agosto 2012, pp. 464-70, DOI:10.1016/j.coph.2012.06.008, PMC 3419278, PMID 22819198.
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ, Therapeutic targeting of Janus kinases, in Immunological Reviews, vol. 223, giugno 2008, pp. 132-42, DOI:10.1111/j.1600-065X.2008.00644.x, PMC 2634846, PMID 18613833.
Norman P, Selective JAK inhibitors in development for rheumatoid arthritis, in Expert Opinion on Investigational Drugs, vol. 23, n. 8, agosto 2014, pp. 1067-77, DOI:10.1517/13543784.2014.918604, PMID 24818516.
Forster M, Gehringer M, Laufer SA, Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting, in Bioorganic & Medicinal Chemistry Letters, vol. 27, n. 18, settembre 2017, pp. 4229-4237, DOI:10.1016/j.bmcl.2017.07.079, PMID 28844493.
Vaddi K, Sarlis NJ, Gupta V, Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis, in Expert Opinion on Pharmacotherapy, vol. 13, n. 16, novembre 2012, pp. 2397-407, DOI:10.1517/14656566.2012.732998, PMID 23051187.
Ruxolitinib (Jakafi) for myelofibrosis, in The Medical Letter on Drugs and Therapeutics, vol. 54, n. 1387, aprile 2012, pp. 27-8, PMID 22469651.
Ostojic A, Vrhovac R, Verstovsek S, Ruxolitinib for the treatment of myelofibrosis, in Drugs of Today, vol. 47, n. 11, novembre 2011, pp. 817-27, DOI:10.1358/dot.2011.47.11.1708829, PMID 22146225.
Mesa RA, Yasothan U, Kirkpatrick P, Ruxolitinib, in Nature Reviews. Drug Discovery, vol. 11, n. 2, febbraio 2012, pp. 103-4, DOI:10.1038/nrd3652, PMID 22293561.
Zerbini CA, Lomonte AB, Tofacitinib for the treatment of rheumatoid arthritis, in Expert Review of Clinical Immunology, vol. 8, n. 4, maggio 2012, pp. 319-31, DOI:10.1586/eci.12.19, PMID 22607178.
Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M, Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy, in Journal of Veterinary Pharmacology and Therapeutics, vol. 37, n. 4, agosto 2014, pp. 317-24, DOI:10.1111/jvp.12101, PMC 4265276, PMID 24495176.
Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A, Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate, in Arthritis & Rheumatology, vol. 69, n. 4, aprile 2017, pp. 709-719, DOI:10.1002/art.39955, PMID 27748083.
Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH, Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis, in Arthritis & Rheumatology, vol. 69, n. 5, maggio 2017, pp. 932-942, DOI:10.1002/art.40054, PMID 28118538.
Markham A, Keam SJ, Peficitinib: First Global Approval, in Drugs, vol. 79, n. 8, giugno 2019, pp. 887-891, DOI:10.1007/s40265-019-01131-y, PMID 31093950.
Liu D, Mamorska-Dyga A, Syk inhibitors in clinical development for hematological malignancies, in Journal of Hematology & Oncology, vol. 10, n. 1, luglio 2017, p. 145, DOI:10.1186/s13045-017-0512-1, PMC 5534090, PMID 28754125.
Shabbir M, Stuart R, Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside, in Expert Opinion on Investigational Drugs, vol. 19, n. 3, marzo 2010, pp. 427-36, DOI:10.1517/13543781003598862, PMID 20141349.
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW, SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies, in Leukemia, vol. 25, n. 11, novembre 2011, pp. 1751-9, DOI:10.1038/leu.2011.148, PMID 21691275.
Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM, Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice, in Cancer Research, vol. 63, n. 6, marzo 2003, pp. 1270-9, PMID 12649187.
Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL, CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms, in Cancer Cell, vol. 28, n. 1, luglio 2015, pp. 15-28, DOI:10.1016/j.ccell.2015.06.006, PMC 4503933, PMID 26175413.
Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM, Pharmacologic inhibition of JAK-STAT signaling promotes hair growth, in Science Advances, vol. 1, n. 9, ottobre 2015, pp. e1500973, Bibcode:2015SciA....1E0973H, DOI:10.1126/sciadv.1500973, PMC 4646834, PMID 26601320.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A, Janus kinase inhibitors in dermatology: A systematic review, in Journal of the American Academy of Dermatology, vol. 76, n. 4, aprile 2017, pp. 745–753.e19, DOI:10.1016/j.jaad.2016.12.004, PMID 28169015.
Furumoto Y, Gadina M, The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders, in BioDrugs, vol. 27, n. 5, ottobre 2013, pp. 431-8, DOI:10.1007/s40259-013-0040-7, PMC 3778139, PMID 23743669.

oadoi.org

Norman P, Selective JAK inhibitors in development for rheumatoid arthritis, in Expert Opinion on Investigational Drugs, vol. 23, n. 8, agosto 2014, pp. 1067-77, DOI:10.1517/13543784.2014.918604, PMID 24818516.
Forster M, Gehringer M, Laufer SA, Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting, in Bioorganic & Medicinal Chemistry Letters, vol. 27, n. 18, settembre 2017, pp. 4229-4237, DOI:10.1016/j.bmcl.2017.07.079, PMID 28844493.
Vaddi K, Sarlis NJ, Gupta V, Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis, in Expert Opinion on Pharmacotherapy, vol. 13, n. 16, novembre 2012, pp. 2397-407, DOI:10.1517/14656566.2012.732998, PMID 23051187.
Ostojic A, Vrhovac R, Verstovsek S, Ruxolitinib for the treatment of myelofibrosis, in Drugs of Today, vol. 47, n. 11, novembre 2011, pp. 817-27, DOI:10.1358/dot.2011.47.11.1708829, PMID 22146225.
Mesa RA, Yasothan U, Kirkpatrick P, Ruxolitinib, in Nature Reviews. Drug Discovery, vol. 11, n. 2, febbraio 2012, pp. 103-4, DOI:10.1038/nrd3652, PMID 22293561.
Zerbini CA, Lomonte AB, Tofacitinib for the treatment of rheumatoid arthritis, in Expert Review of Clinical Immunology, vol. 8, n. 4, maggio 2012, pp. 319-31, DOI:10.1586/eci.12.19, PMID 22607178.
Kivitz AJ, Gutierrez-Ureña SR, Poiley J, Genovese MC, Kristy R, Shay K, Wang X, Garg JP, Zubrzycka-Sienkiewicz A, Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate, in Arthritis & Rheumatology, vol. 69, n. 4, aprile 2017, pp. 709-719, DOI:10.1002/art.39955, PMID 27748083.
Genovese MC, Greenwald M, Codding C, Zubrzycka-Sienkiewicz A, Kivitz AJ, Wang A, Shay K, Wang X, Garg JP, Cardiel MH, Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis, in Arthritis & Rheumatology, vol. 69, n. 5, maggio 2017, pp. 932-942, DOI:10.1002/art.40054, PMID 28118538.
Markham A, Keam SJ, Peficitinib: First Global Approval, in Drugs, vol. 79, n. 8, giugno 2019, pp. 887-891, DOI:10.1007/s40265-019-01131-y, PMID 31093950.
Shabbir M, Stuart R, Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside, in Expert Opinion on Investigational Drugs, vol. 19, n. 3, marzo 2010, pp. 427-36, DOI:10.1517/13543781003598862, PMID 20141349.
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW, SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies, in Leukemia, vol. 25, n. 11, novembre 2011, pp. 1751-9, DOI:10.1038/leu.2011.148, PMID 21691275.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A, Janus kinase inhibitors in dermatology: A systematic review, in Journal of the American Academy of Dermatology, vol. 76, n. 4, aprile 2017, pp. 745–753.e19, DOI:10.1016/j.jaad.2016.12.004, PMID 28169015.

pfizer.com

labeling.pfizer.com

Xeljanz (tofacitinib) Tablets, for Oral Use and Xeljanz XR (tofacitinib) Extended Release Tablets, for Oral Use. Full Prescribing Information, su labeling.pfizer.com, Pfizer Labs. Division of Pfizer, Inc. NY, NY 10017. URL consultato il 16 luglio 2016.

pfizer.com

Pfizer Press Release Cibinqo, Jan 14, 2022, su pfizer.com.

web.archive.org

FDA Approves Apoquel (oclacitinib tablet) to Control Itch and Inflammation in Allergic Dogs, su news.zoetis.com, Zoetis, 16 maggio 2013. URL consultato il 23 febbraio 2017 (archiviato dall'url originale il 23 febbraio 2017).
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis, su ir.celgene.com. URL consultato il 16 agosto 2019 (archiviato dall'url originale il 16 agosto 2019).
J Stallard, Discovery Could Boost New Therapies for Myeloproliferative Neoplasms, in Memorial Sloan Kettering Cancer Center, 23 luglio 2015. URL consultato il 16 luglio 2016 (archiviato dall'url originale il 16 giugno 2016).

yale.edu

news.yale.edu

E Gershon, In Hairless Man, Arthritis Drug Spurs Hair Growth — Lots of It, in Yale News, 19 giugno 2014. URL consultato il 16 luglio 2016.

zoetisus.com

Apoquel (oclacitinib maleate tablet) Full Prescribing Information (PDF), su zoetisus.com, Zoetis Inc. Kalamazoo, MI 49007. URL consultato il 23 febbraio 2017.